Zomedica Introduces Enhanced Audio Features for the VETGuardian(R) Zero-touch Vital Signs Remote Monitoring System
Zomedica Corp. (NYSE American:ZOM) has introduced advanced audio capabilities for its VETGuardian Zero-touch remote vital signs monitoring system. The new features include real-time audio streaming, recorded playback functionality, and customizable alerts. These enhancements aim to revolutionize remote patient monitoring in veterinary medicine by providing veterinarians with more comprehensive insights into animal health.
The VETGuardian system is now the only product on the market offering contactless vital sign monitoring combined with live video and audio feed. This unique combination allows for detailed remote assessments of animals, enabling early detection of distress signs, evaluation of treatment responses, and more precise care delivery. The audio recording feature also supports improved documentation and medical record-keeping, facilitating better-informed decision-making in veterinary care.
Zomedica Corp. (NYSE American:ZOM) ha introdotto capacità audio avanzate per il suo sistema di monitoraggio remoto dei segni vitali VETGuardian a zero contatto. Le nuove funzionalità includono streaming audio in tempo reale, funzionalità di riproduzione registrata e avvisi personalizzabili. Questi miglioramenti mirano a rivoluzionare il monitoraggio remoto dei pazienti nella medicina veterinaria, fornendo ai veterinari informazioni più complete sulla salute degli animali.
Il sistema VETGuardian è ora l'unico prodotto sul mercato che offre monitoraggio dei segni vitali senza contatto, combinato con video e audio in diretta. Questa combinazione unica consente valutazioni dettagliate a distanza degli animali, facilitando la rilevazione precoce dei segni di disagio, la valutazione delle risposte al trattamento e la fornitura di cure più precise. La funzionalità di registrazione audio supporta anche una migliore documentazione e gestione delle cartelle cliniche, facilitando decisioni più informate nella cura veterinaria.
Zomedica Corp. (NYSE American:ZOM) ha presentado capacidades de audio avanzadas para su sistema de monitoreo remoto de signos vitales VETGuardian sin contacto. Las nuevas funciones incluyen transmisión de audio en tiempo real, funcionalidad de reproducción grabada y alertas personalizables. Estas mejoras tienen como objetivo revolucionar el monitoreo remoto de pacientes en la medicina veterinaria, brindando a los veterinarios información más completa sobre la salud animal.
El sistema VETGuardian es ahora el único producto en el mercado que ofrece monitoreo de signos vitales sin contacto combinado con video y audio en vivo. Esta combinación única permite evaluaciones remotas detalladas de los animales, habilitando la detección temprana de señales de angustia, la evaluación de las respuestas al tratamiento y la entrega de una atención más precisa. La función de grabación de audio también apoya una mejor documentación y mantenimiento de registros médicos, facilitando una toma de decisiones más informada en la atención veterinaria.
조메디카 코프(Zomedica Corp., NYSE American: ZOM)가 비접촉 원격 생체 신호 모니터링 시스템인 VETGuardian에 고급 오디오 기능을 도입했습니다. 새로운 기능에는 실시간 오디오 스트리밍, 녹음 재생 기능 및 사용자 정의 알림이 포함됩니다. 이러한 개선은 수의학에서 원격 환자 모니터링을 혁신하여 수의사들에게 동물 건강에 대한 더 포괄적인 통찰력을 제공하는 것을 목표로 하고 있습니다.
VETGuardian 시스템은 이제 실시간 비디오 및 오디오 피드와 결합된 비접촉 생체 신호 모니터링을 제공하는 시장에서 유일한 제품입니다. 이 독특한 조합은 동물의 원격 평가를 상세하게 수행하여, 불편의 징후를 조기에 발견하고 치료 반응을 평가하며 보다 정확한 치료를 제공할 수 있게 합니다. 오디오 녹음 기능은 또한 기록 유지 및 의료 기록 관리를 개선하여 수의 진료에서 더 잘-informed 결정을 내리는 데 도움을 줍니다.
Zomedica Corp. (NYSE American:ZOM) a introduit des capacités audio avancées pour son système VETGuardian de surveillance des signes vitaux à distance sans contact. Les nouvelles fonctionnalités comprennent le streaming audio en temps réel, la fonction de lecture enregistrée et des alertes personnalisables. Ces améliorations visent à révolutionner la surveillance à distance des patients en médecine vétérinaire en offrant aux vétérinaires des informations plus complètes sur la santé animale.
Le système VETGuardian est désormais le seul produit sur le marché à proposer une surveillance des signes vitaux sans contact combinée avec un flux vidéo et audio en direct. Cette combinaison unique permet des évaluations détaillées à distance des animaux, facilitant la détection précoce des signes de détresse, l'évaluation des réponses aux traitements et une prestation de soins plus précise. La fonctionnalité d'enregistrement audio favorise également une meilleure documentation et gestion des dossiers médicaux, permettant ainsi une prise de décision mieux informée en matière de soins vétérinaires.
Zomedica Corp. (NYSE American:ZOM) hat erweiterte Audiofunktionen für sein VETGuardian-System zur kontaktlosen Überwachung der Vitalzeichen eingeführt. Zu den neuen Funktionen gehören Echtzeit-Audio-Streaming, die Möglichkeit der Wiedergabe von Aufnahmen und anpassbare Warnmeldungen. Diese Verbesserungen zielen darauf ab, die Fernüberwachung von Patienten in der Veterinärmedizin zu revolutionieren, indem sie Tierärzten umfassendere Einblicke in die Gesundheit der Tiere bieten.
Das VETGuardian-System ist jetzt das einzige Produkt auf dem Markt, das kontaktlose Vitalzeichenüberwachung in Kombination mit Live-Video- und Audioübertragung anbietet. Diese einzigartige Kombination ermöglicht detaillierte Fernbewertungen von Tieren, wodurch frühe Anzeichen von Stress erkannt, Behandlungsergebnisse bewertet und eine präzisere Versorgung gewährleistet werden können. Die Audioaufzeichnungsfunktion unterstützt zudem eine verbesserte Dokumentation und medizinische Aufzeichnungen, was fundiertere Entscheidungen in der veterinärmedizinischen Versorgung erleichtert.
- Introduction of advanced audio capabilities for VETGuardian system
- Unique market position as the only contactless vital sign monitoring system with live video and audio feed
- Enhanced ability for veterinarians to detect early signs of distress and assess treatment responses
- Improved documentation and medical record-keeping through audio recording feature
- None.
The introduction of advanced audio features to Zomedica's VETGuardian system marks a significant leap in veterinary monitoring technology. Real-time audio streaming and playback functionality offer veterinarians unprecedented insights into animal health, potentially improving patient outcomes and care efficiency. This innovation addresses a critical gap in remote monitoring, allowing for more comprehensive assessments without physical contact.
The system's unique combination of contactless vital sign monitoring with live video and audio feed positions Zomedica as a pioneer in the veterinary tech market. This could translate to increased market share and revenue growth for the company. However, the true test will be in the system's adoption rate and its ability to demonstrate tangible improvements in veterinary care quality and efficiency.
The enhanced VETGuardian system could be a game-changer for veterinary practices, especially those offering overnight care. The ability to remotely monitor patients through audio and video feeds may reduce staff workload and improve animal safety. This could lead to increased efficiency and potentially higher profit margins for clinics adopting the technology.
However, the success of this product will depend on its ease of integration into existing workflows and its cost-effectiveness. Veterinary practices may need to weigh the initial investment against long-term benefits. If Zomedica can demonstrate clear ROI and improved patient outcomes, we could see widespread adoption, potentially boosting the company's revenue and market position in the veterinary technology sector.
While Zomedica's VETGuardian enhancement is innovative, its financial impact remains uncertain. The company's focus on technological advancement in the veterinary sector is commendable, but investors should consider several factors:
- Market adoption rate and speed
- Pricing strategy and profit margins
- Competition in the veterinary monitoring space
Zomedica's success will hinge on effectively monetizing this technology and achieving widespread adoption. The company's ability to translate innovation into revenue growth and profitability will be crucial. Investors should monitor upcoming financial reports for indicators of VETGuardian's market traction and its contribution to Zomedica's overall financial health. While promising, it's too early to determine if this will significantly impact the company's stock performance in the short term.
Increased functionality makes the VETGuardian system a must have for veterinarians
ANN ARBOR, MI / ACCESSWIRE / August 22, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company", a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, announced the introduction of advanced audio capabilities for its VETGuardian Zero-touch remote vital signs monitoring system, poised to revolutionize remote patient monitoring in veterinary medicine. These cutting-edge features include real-time audio streaming, recorded playback functionality, and customizable alerts, empowering veterinarians with unparalleled insights into animal health through auditory data.
"With live audio monitoring and recorded playback, the VETGuardian system represents a major leap forward in veterinary care," stated Evan St. Peter, Vice President of technology Innovation at Zomedica. "These sophisticated tools enable veterinarians to detect subtle nuances in animal behavior and health, facilitating enhanced monitoring."
Dr. Scott Baldwin of Woodland Veterinary Center added, "VetGuardian gives a doctor peace of mind and lowers anxiety when patients have to stay overnight in the hospital."
The VetGuardian monitor stands out as the only system on the market offering contactless vital sign monitoring, coupled with a live video and audio feed. This unique combination allows veterinarians to assess animals remotely with unprecedented detail and responsiveness.
"Veterinarians rely on detailed assessments to provide optimal care," stated Scott Ijaz, Senior Product Manager at Zomedica. "The audio features of the VETGuardian system allow them to not only visually observe but also the option to audibly monitor an animal's condition. This capability is crucial for detecting early signs of distress, assessing response to treatment, and ultimately delivering more precise and compassionate care."
The ability to review audio recordings allows veterinarians to document vocalizations that may indicate pain, discomfort, or improvements in recovery over time. This detailed data enhances medical records and provides a comprehensive view of the animal's progress, supporting informed decision-making and enhancing patient care outcomes.
From identifying early signs of distress to monitoring treatment responses, the VETGuardian system's advanced audio capabilities enhance veterinary care coordination and decision-making, setting a new standard in animal health monitoring solutions.
For more detailed information on VetGuardian and its latest features, please visit Zomedica's official website at www.zomedica.com.
About Zomedica
Zomedica is a leading equine and companion animal healthcare company dedicated to improving animal health by providing veterinarians innovative therapeutic and diagnostic solutions. Our gold standard PulseVet® shock wave system, which accelerates healing in musculoskeletal conditions, has transformed veterinary therapeutics. Our suite of products also includes the Assisi® Loop line of therapeutic devices and the TRUFORMA® diagnostic platform, the TRUVIEW™ digital cytology system, and the VetGuardian® no-touch monitoring system, all designed to empower veterinarians to provide top-tier care. In the aggregate, their total addressable market in the U.S. exceeds
Follow Zomedica
Email Alerts: http://investors.zomedica.com
Facebook: https://m.facebook.com/zomedica
X (formerly Twitter): https://twitter.com/zomedica
Instagram: https://www.instagram.com/zomedica_inc
Cautionary Note Regarding Forward-Looking Statements
Except for statements of historical fact, this news release contains certain "forward-looking information" or "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance, or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.
Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to economic growth, demand for the Company's products, the Company's ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements, our ability to realize upon our business plans and cost control efforts and the impact of COVID-19 on our business, results and financial condition.
Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: continued growth of sales, the outcome of clinical studies, the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work; uncertainty as to the timing and results of verification and validation studies; uncertainty as to the timing and results of commercialization efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to successfully integrate acquisitions; uncertainty as to our ability to supply products in response to customer demand; and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including product manufacturing obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, risks related to the COVID-19 pandemic and its impact upon our business operations generally, including our ability to develop and commercialize our products, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR+ at www.sedarplus.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.
The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.
Investor Relations Contact:
Zomedica Investor Relations
investors@zomedica.com
1-734-369-2555
SOURCE: Zomedica Corp.
View the original press release on accesswire.com
FAQ
What new features has Zomedica (ZOM) added to its VETGuardian system?
How does the VETGuardian system by Zomedica (ZOM) differ from other veterinary monitoring systems?
What benefits do the new audio features of Zomedica's (ZOM) VETGuardian system provide to veterinarians?
When did Zomedica (ZOM) announce the enhanced audio features for VETGuardian?
